| Aug 9 |
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
| Aug 8 |
Mirum's (MIRM) Q2 Earnings Lag Estimates, Revenues Top
|
| Aug 7 |
Mirum Pharmaceuticals GAAP EPS of -$0.52 misses by $0.04, revenue of $77.8M beats by $2.58M
|
| Aug 7 |
Mirum Pharmaceuticals, Inc. (MIRM) Reports Q2 Loss, Tops Revenue Estimates
|
| Aug 7 |
Mirum Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update
|
| Jul 31 |
Mirum Pharmaceuticals to Announce Second Quarter 2024 Financial Results and Host Conference Call on August 7, 2024
|
| Jul 29 |
Mirum Pharmaceuticals (MIRM) Surges 7.3%: Is This an Indication of Further Gains?
|
| Jul 26 |
Mirum Pharma gains amid report of approach from Swedish Orphan Biovitrum
|
| Jul 25 |
Mirum granted FDA label expansion for lead drug in liver disease
|
| Jul 25 |
Mirum’s LIVMARLI Now Approved for PFIC in Patients 12 Months and Older
|
